IL117564A - Pharmaceutical and diagnostic compositions containing lysine derivatives - Google Patents

Pharmaceutical and diagnostic compositions containing lysine derivatives

Info

Publication number
IL117564A
IL117564A IL11756496A IL11756496A IL117564A IL 117564 A IL117564 A IL 117564A IL 11756496 A IL11756496 A IL 11756496A IL 11756496 A IL11756496 A IL 11756496A IL 117564 A IL117564 A IL 117564A
Authority
IL
Israel
Prior art keywords
pharmaceutical
compositions containing
diagnostic compositions
containing lysine
lysine derivatives
Prior art date
Application number
IL11756496A
Other languages
English (en)
Other versions
IL117564A0 (en
Original Assignee
Ct Molecular Med & Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Molecular Med & Immunology filed Critical Ct Molecular Med & Immunology
Publication of IL117564A0 publication Critical patent/IL117564A0/xx
Publication of IL117564A publication Critical patent/IL117564A/xx

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6895Rescue therapy; Agonist-antagonist; Antidotes; Targeted rescue or protection, e.g. by folic acid-folinic acid or conjugated to antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL11756496A 1995-03-21 1996-03-20 Pharmaceutical and diagnostic compositions containing lysine derivatives IL117564A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/407,899 US5843894A (en) 1995-03-21 1995-03-21 Methods for reduced renal uptake of antibody fragments

Publications (2)

Publication Number Publication Date
IL117564A0 IL117564A0 (en) 1996-07-23
IL117564A true IL117564A (en) 2005-03-20

Family

ID=23614010

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11756496A IL117564A (en) 1995-03-21 1996-03-20 Pharmaceutical and diagnostic compositions containing lysine derivatives

Country Status (9)

Country Link
US (4) US5843894A (de)
EP (1) EP0767673B1 (de)
JP (1) JPH10505866A (de)
AT (1) ATE254469T1 (de)
CA (1) CA2190867C (de)
DE (1) DE69630761T2 (de)
ES (1) ES2211951T3 (de)
IL (1) IL117564A (de)
WO (1) WO1996029087A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
EP1187637A2 (de) * 1999-06-07 2002-03-20 Center For Molecular Medicine And Immunology Alpha und beta strahlern angekoppelt zu fragmente im radioimmunotherapie
AU6275800A (en) * 1999-07-16 2001-02-05 Mallinckrodt, Inc. Inhibition of renal uptake of molecules that are potentially damaging for the kidney
EP1862172A1 (de) * 2006-05-31 2007-12-05 BioSynthema Inc. Zusammensetzung von einer Aminosäurelösung und Gelatine zur Hemmung renaler Aufnahme
WO2013106824A1 (en) * 2012-01-13 2013-07-18 Board Of Regents, The University Of Texas System Epherin receptor targeting agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283342A (en) * 1992-06-09 1994-02-01 Neorx Corporation Biotinylated small molecules
US4701521A (en) * 1978-07-17 1987-10-20 The Trustees Of Boston University Method of effecting cellular uptake of molecules
US5595734A (en) * 1988-04-06 1997-01-21 Alfacell Corporation Compositions comprising ONCONASE (tm) and lovastatin
ATE136224T1 (de) * 1989-09-29 1996-04-15 Neorx Corp Reduktion der nichtzielspezifischen retention von immunokonjugaten und ihren metaboliten
US5225180A (en) * 1991-09-10 1993-07-06 Diatech, Inc. Technetium-99m labeled somatostatin-derived peptides for imaging
US5843894A (en) * 1995-03-21 1998-12-01 Center For Molecular Medicine And Immunology Methods for reduced renal uptake of antibody fragments
US5840296A (en) * 1997-10-15 1998-11-24 Raines; Ronald T. Engineered cytotoxic ribonuclease A

Also Published As

Publication number Publication date
IL117564A0 (en) 1996-07-23
US20060182683A1 (en) 2006-08-17
US20020111300A1 (en) 2002-08-15
CA2190867A1 (en) 1996-09-26
ATE254469T1 (de) 2003-12-15
US20030203836A1 (en) 2003-10-30
DE69630761T2 (de) 2004-09-23
AU700346B2 (en) 1999-01-07
AU5361696A (en) 1996-10-08
EP0767673A1 (de) 1997-04-16
EP0767673B1 (de) 2003-11-19
EP0767673A4 (de) 1999-08-04
JPH10505866A (ja) 1998-06-09
DE69630761D1 (de) 2003-12-24
WO1996029087A1 (en) 1996-09-26
CA2190867C (en) 2009-06-02
ES2211951T3 (es) 2004-07-16
US5843894A (en) 1998-12-01

Similar Documents

Publication Publication Date Title
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
NO20015584L (no) Langtidsvarende insulintropiske peptider og konjugater samt anvendelse for fremstilling av medikamenter for behandling
JPH09508141A (ja) ビタミンb▲下12▼とタンパク質との複合体
UA41446C2 (uk) Застосування фумагілолу та його похідних для одержання ліків, призначених для боротьби з кишковими інфекціями, та фармацевтична композиція на їх основі
BG101118A (en) Therapeutical compounds
EP0701448A4 (de) Erweiterung des vitamin b 12 - aufnahmesystems unter verwendung von polymeren
BR0112591A (pt) Derivados de acridina e sua aplicação como medicamento
NO972968D0 (no) Fremgangsmåte, sammensetninger og sett for öking av oral biotilgjengelighet av farmasöytiske midler
IL87740A (en) Glycosyl-modified antibodies and antibody conjugates for enhanced clearance, pharmaceutical and diagnostic preparations containing the same, methods for the production thereof and diagnostic methods utilizing the same
DE69829175D1 (de) Cyclosporinderivate, deren herstellung und pharmazeutische zubereitungen
AR022252A1 (es) Composicion de administracion oral.
DE69230500D1 (de) Pharmazeutische Dipeptid Zusammensetzungen und Verwendungsmethoden.
WO1992019213A3 (en) Enhancement of abnormal tissue uptake of antibodies, tumor-specific agents or conjugates thereof for diagnostic imaging or therapy
BR0016339A (pt) Composição de lcrf, conjugado de lcrf, composição de peptìdeo, complexo de lcrf conjugado a ligando múltiplo, complexo de polissorbato, complexo de lcrf conjugado, aquosamente solúvel estável, forma de dosagem de administração oral para o tratamento da obesidade, métodos de tratamento da obesidade em um paciente mamìfero humano ou não humano, de tratamento modo profilático ou intervencional da obesidade potencial ou desenvolvida em um paciente mamìfero humano ou não humano e de prolongamento da atividade de lcrf em um sistema in vivo ou in vitro, e, composto
DE69812727D1 (de) Opioid-konjugate mit endogenen Trägerproteinen
PL345959A1 (en) Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate
WO1999007401A3 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
EE04606B1 (et) H+, K+-ATPaasi inhibiitori kasutamine ravimi valmistamiseks peroraalseks manustamiseks
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
KR970025615A (ko) 암 전이 억제제
DE69125715D1 (de) Heterozyklische verbindungen
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
ATE196768T1 (de) Neue 6-hydroxy und 6-oxo-androstan verbindungen mit kardioaktivität und pharmazeutische präparate davon
CA2038744A1 (en) Pharmaceutical composition containing slightly water-soluble drug
IL136733A0 (en) Pharmaceutical composition containing sibutramine and orlistat

Legal Events

Date Code Title Description
FF Patent granted